The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection
Open accessAbstract
Export Late antibody-mediated rejection (ABMR) is a leading cause of kidney allograft failure. Uncontrolled studies have suggested efficacy of the proteasome inhibitor bortezomib, but no systematic trial has been undertaken to support its use in ABMR. In this randomized, placebo-controlled trial (the Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection [BORTEJECT] Trial), we investigated whether two cycles of bortezomib (each cycle: 1.3 mg/m2 intravenously on days 1, 4, 8, and 11) prevent GFR decline by halting the progression of late donor-specific antibody (DSA)–positive ABMR. Forty-four DSA-positive kidney transplant recipients with characteristic ABMR morphology (median time after transplant, 5.0 years; pretransplant DSA documented in 19 recipients), who were identified on cross-sectional screening of 741 patients, were randomly assigned to receive bortezomib (n=21) or placebo (n=23). The 0.5-ml/min per 1.73 m2 per year (95% confidence interval, −4.8 to 5.8) difference detected between bortezomib and placebo in eGFR slope (primary end point) was not significant (P=0.86). We detected no significant differences between bortezomib- and placebo-treated groups in median measured GFR at 24 months (33 versus 42 ml/min per 1.73 m2; P=0.31), 2-year graft survival (81% versus 96%; P=0.12), urinary protein concentration, DSA levels, or morphologic or molecular rejection phenotypes in 24-month follow-up biopsy specimens. Bortezomib, however, associated with gastrointestinal and hematologic toxicity. In conclusion, our trial failed to show that bortezomib prevents GFR loss, improves histologic or molecular disease features, or reduces DSA, despite significant toxicity. Our results reinforce the need for systematic trials to dissect the efficiency and safety of new treatments for late ABMR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sellarés, J., de Freitas, D. G., Mengel, M., Reeve, J., Einecke, G., Sis, B., Hidalgo, L. G., Famulski, K., Matas, A., & Halloran, P. F. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03840.x · Cited by 1,590
Self-citationHaas, M., Sis, B., Racusen, L. C., Solez, K., Glotz, D., Colvin, R. B., Castro, M. C. R., David, D. S. R., David-Neto, E., Bagnasco, S. M., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12590 · Cited by 1,350
Rule, A. D., Larson, T. S., Bergstralh, E. J., Slezak, J. M., Jacobsen, S. J., & Cosio, F. G. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-12-200412210-00009 · Cited by 1,066
Proteasome inhibitors in cancer therapy
Manasanch, E. E., & Orlowski, R. Z. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.206 · Cited by 1,024
Coresh, J., Turin, T. C., Matsushita, K., Sang, Y., Ballew, S. H., Appel, L. J., Arima, H., Chadban, S. J., Cirillo, M., Djurdjev, O., et al. (2014) · JAMA · doi:10.1001/jama.2014.6634 · Cited by 988
Moreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70081-x · Cited by 920
Dimopoulos, M. A., Moreau, P., Palumbo, A., Joshua, D., Pour, L., Hájek, R., Facon, T., Ludwig, H., Oriol, A., Goldschmidt, H., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00464-7 · Cited by 857
Loupy, A., Haas, M., Solez, K., Racusen, L., Glotz, D., Seron, D., Nankivell, B. J., Colvin, R. B., Afrouzian, M., Akalin, E., et al. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14107 · Cited by 629
Neubert, K., Meister, S., Moser, K., Weisel, F., Maseda, D., Amann, K., Wiethe, C., Winkler, T. H., Kalden, J. R., Manz, R. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1763 · Cited by 584
Interim analysis: The alpha spending function approach
Demets, D. L., & Lan, K. K. G. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131308 · Cited by 564
Extensive Immunoglobulin Production Sensitizes Myeloma Cells for Proteasome Inhibition
Meister, S., Schubert, U., Neubert, K., Herrmann, K., Burger, R., Gramatzki, M., Hahn, S., Schreiber, S., Wilhelm, S., Herrmann, M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2258 · Cited by 410
Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection
Everly, M. J., Everly, J. J., Susskind, B., Brailey, P., Arend, L. J., Alloway, R. R., Roy-Chaudhury, P., Govil, A., Mogilishetty, G., Rike, A. H., et al. (2008) · Transplantation · doi:10.1097/tp.0b013e318190af83 · Cited by 392
Choi, J., Aubert, O., Vo, A., Loupy, A., Haas, M., Puliyanda, D., Kim, I., Louie, S., Kang, A., Peng, A., et al. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14228 · Cited by 355
Perry, D. K., Burns, J. M., Pollinger, H. S., Amiot, B. P., Gloor, J. M., Gores, G. J., & Stegall, M. D. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02461.x · Cited by 329
Halloran, P. F., Reeve, J., Akalin, E., Aubert, O., Bohmig, G. A., Brennan, D., Bromberg, J., Einecke, G., Eskandary, F., Gosset, C., et al. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14329 · Cited by 190
Self-citationReeve, J., Böhmig, G. A., Eskandary, F., Einecke, G., Lefaucheur, C., Loupy, A., & Halloran, P. F. (2017) · JCI Insight · doi:10.1172/jci.insight.94197 · Cited by 181
Self-citationMolecular assessment of disease states in kidney transplant biopsy samples
Halloran, P. F., Famulski, K. S., & Reeve, J. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.85 · Cited by 179
Self-citationAbrogation of Anti-HLA Antibodies via Proteasome Inhibition
Trivedi, H. L., Terasaki, P. I., Feroz, A., Everly, M. J., Vanikar, A. V., Shankar, V., Trivedi, V. B., Kaneku, H., Idica, A. K., Modi, P. R., et al. (2009) · Transplantation · doi:10.1097/tp.0b013e3181a4b91b · Cited by 164
Walsh, R. C., Brailey, P., Girnita, A., Alloway, R. R., Shields, A. R., Wall, G. E., Sadaka, B. H., Cardi, M., Tevar, A., Govil, A., et al. (2011) · Transplantation · doi:10.1097/tp.0b013e318218e901 · Cited by 162
Theruvath, T. P., Saidman, S. L., Mauiyyedi, S., Delmonico, F. L., Williams, W. W., TOLKOFF-RUBIN, N. E., Collins, A. B., Colvin, R. B., Cosimi, A. B., & Pascual, M. A. (2001) · Transplantation · doi:10.1097/00007890-200107150-00016 · Cited by 152
Prospective Iterative Trial of Proteasome Inhibitor-Based Desensitization
Woodle, E. S., Shields, A. R., Ejaz, N. S., Sadaka, B. H., Girnita, A. L., Walsh, R. C., Alloway, R. R., Brailey, P. A., Cardi, M. A., Jawdeh, B. G. A., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.13050 · Cited by 149
Proteasome inhibitors as experimental therapeutics of autoimmune diseases
Verbrugge, S. E., Scheper, R. J., Lems, W. F., de Gruijl, T. D., & Jansen, G. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0529-1 · Cited by 137
Waiser, J., Budde, K., Schutz, M., Liefeldt, L., Rudolph, B. D., Schönemann, C., Neumayer, H.-H., & Lachmann, N. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr465 · Cited by 127
Sberro‐Soussan, R., Zuber, J., Suberbielle, C., Candon, S., Martinez, F., Snanoudj, R., Rabant, M., Pallet, N., Nochy, D., Anglicheau, D., et al. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02968.x · Cited by 121
Relationship between eGFR Decline and Hard Outcomes after Kidney Transplants
Clayton, P. A., Lim, W. H., Wong, G., & Chadban, S. J. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015050524 · Cited by 116
Humoral Compensation after Bortezomib Treatment of Allosensitized Recipients
Kwun, J., Burghuber, C. K., Manook, M., Iwakoshi, N. N., Gibby, A., Hong, J. J., & Knechtle, S. J. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016070727 · Cited by 85
The Impact of Proteasome Inhibition on Alloantibody-Producing Plasma Cells In Vivo
Diwan, T. S., Raghavaiah, S., Burns, J. M., Kremers, W. K., Gloor, J. M., & Stegall, M. D. (2011) · Transplantation · doi:10.1097/tp.0b013e3182081333 · Cited by 77
Eskandary, F. A., Bond, G., Kozakowski, N., Regele, H. M., Marinova, L., Wahrmann, M., Kikić, Ž., Haslacher, H., Rasoul‐Rockenschaub, S., Kaltenecker, C. C., et al. (2016) · Transplantation · doi:10.1097/tp.0000000000001195 · Cited by 71
Self-citationGFR Decline as an End Point in Trials of CKD: A Viewpoint From the FDA
Thompson, A., Lawrence, J., & Stockbridge, N. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.09.006 · Cited by 66
Guthoff, M., Schmid-Horch, B. D., Weisel, K. C., Häring, H., Königsrainer, A., & Heyne, N. (2012) · Transplant Immunology · doi:10.1016/j.trim.2012.01.002 · Cited by 48
Schmidt, N., Alloway, R. R., Walsh, R. C., Sadaka, B. H., Shields, A. R., Girnita, A. L., Hanseman, D. J., & Woodle, E. S. (2012) · Transplantation · doi:10.1097/tp.0b013e318257acf6 · Cited by 43
The Proteasome in Terminal Plasma Cell Differentiation
Cenci, S. (2012) · Seminars in Hematology · doi:10.1053/j.seminhematol.2012.04.005 · Cited by 35
Donor-specific HLA antibodies and renal allograft failure
Loupy, A., & Jordan, S. C. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.18 · Cited by 34
Cited by
Velleca, A., Shullo, M. A., Dhital, K., Azeka, E., Colvin, M., DePasquale, E., Farrero, M., García-Guereta, L., Jamero, G., Khush, K., et al. (2023) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.10.015 · Cited by 645
Antibody-Mediated Rejection of Solid-Organ Allografts
Loupy, A., & Lefaucheur, C. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1802677 · Cited by 549
Loupy, A., Aubert, O., Orandi, B. J., Naesens, M., Bouatou, Y., Raynaud, M., Divard, G., Jackson, A. M., Viglietti, D., Giral, M., et al. (2019) · BMJ · doi:10.1136/bmj.l4923 · Cited by 350
Self-citationSchinstock, C. A., Mannon, R. B., Budde, K., Chong, A. S., Haas, M., Knechtle, S., Lefaucheur, C., Montgomery, R. A., Nickerson, P., Tullius, S. G., et al. (2020) · Transplantation · doi:10.1097/tp.0000000000003095 · Cited by 345
Metadata
- Authors
- Eskandary, F., Regele, H., Baumann, L., Bond, G., Kozakowski, N., Wahrmann, M., Hidalgo, L. G., Haslacher, H., Kaltenecker, C. C., Aretin, M.-B., Oberbauer, R., Posch, M., Staudenherz, A., Handisurya, A., Reeve, J., Halloran, P. F., & Böhmig, G. A.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2017-12-14
- Volume
- 29
- Issue
- 2
- Pages
- 591-605
- ISSN
- 1046-6673 (ISSN-L)
- 1533-3450
- OpenAlex
- W2773812249
- Cited by
- 306
- References
- 33
- FWCI
- 25.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.